GREY:IMVIF - Post by User
Comment by
Breakthoroughon Dec 05, 2020 4:06am
212 Views
Post# 32043330
RE:RE:RE:RE:RE:RE:Comparison with STR-002
RE:RE:RE:RE:RE:RE:Comparison with STR-002More accurately. With the 10 still on treatment (I correct the distribution: 3 below six months, 4 more than 6 months and les than 12 months, 3 more than 12 months), the outcome os this STRO-002 trial (future dose-expansion arms apart) regarding total patients on treatment are: At 6 months, 14-17 (45-55%; DPX, 37%). At 12 months, 4-11 (13-36%, DPX, 26'3%). Very similar, with time apparently playing in favour of DPX, which also has less toxicity. Can't wait for the BT results (three cohorts in ovarian, with and without Pembro and Cy).